Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 003220389 approvals148 trials

DAEWON PHARMACEUTICAL CO.,LTD

Official website

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

As of 2026-10-10, DAEWON PHARMACEUTICAL CO.,LTD has 1 Korean MFDS device approval, 388 Korean MFDS drug approvals, 6 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1961 and listed on KOSPI in 1999, Daewon Pharmaceutical is a comprehensive pharmaceutical company spanning pharmaceuticals, cosmetics, and health functional foods. It sells Coldwon, Korea's first chewable cold medicine, and Jangdaewon, Korea's first organic-certified probiotic supplement, alongside contract manufacturing (CMO) for other drugmakers, finished-drug exports, and the SNP mask pack cosmetics brand of its subsidiary SD Biotechnology. Its licensed drug pipeline includes TU2670 for endometriosis (in-licensed from Tium Bio, European Phase 2a completed), the P-CAB drug DW-4421 for GERD co-developed with Yunovia (domestic Phase 3 ongoing), and the obesity treatment DW-4222 licensed from Glaceum (domestic Phase 2a completed), among several licensed pipeline programs.

Products & technology

  • ColdwonChewable cold medicine (OTC)
  • JangdaewonOrganic-certified probiotic health functional food
  • SNP mask packCosmetics (subsidiary SD Biotechnology)

Regulatory approvals

data.go.kr

388 Korean MFDS drug approvals · 1958–2026 / 1 Korean MFDS device approvals · 2018

  • MFDS drugVonobel Tab.20mg2026-10-02
    Drug · Prescription · Approval202602991
  • MFDS drugVonobel Tab.10mg2026-10-02
    Drug · Prescription · Approval202602992
  • MFDS drugLicure Suspension2026-10-02
    Drug · Prescription · Approval202603001
  • MFDS drugEva-One Tab. 60mg2026-08-31
    Drug · Prescription · Approval202602539
  • MFDS drugEva-One Tab. 30mg2026-08-31
    Drug · Prescription · Approval202602545
  • MFDS drugColdaewon Lergytoc sol.(cetirizine hydrochloride)2026-07-02
    Drug · OTC · Notification202601934
  • MFDS drugPancrawon Tab.2026-06-16
    Drug · OTC · Approval202601702
  • MFDS drugTavalozet 1/10mg2026-05-20
    Drug · Prescription · Approval202601474
  • MFDS drugTwofree Tab.2026-05-03
    Drug · Prescription · Approval202601316
  • MFDS drugDubrugel Solution(Simethicone)2026-04-16
    Drug · OTC · Approval202601107
  • MFDS drugJunod Pre-filled Syringe2026-03-31
    Drug · Prescription · Approval202600898
  • MFDS drugUptava SR Tab.2026-02-25
    Drug · Prescription · Approval202600577
Show 68 more
  • MFDS drugTwynchlor Tab. 40/5/12.5mg(Telmisartan,Amlodipine,Chlorthalidone)2026-01-20
    Drug · Prescription · Approval202600168
  • MFDS drugTwynchlor Tab. 80/5/12.5mg(Telmisartan,Amlodipine,Chlorthalidone)2026-01-20
    Drug · Prescription · Approval202600169
  • MFDS drugTwynchlor Tab. 80/5/25mg(Telmisartan,Amlodipine,Chlorthalidone)2026-01-20
    Drug · Prescription · Approval202600170
  • MFDS drugEnzadex Soft Capsule 40mg2025-12-23
    Drug · Prescription · Approval202503368
  • MFDS drugSaccine Cataplasma(Diclofenac Sodium)2025-12-04
    Drug · OTC · Notification202503165
  • MFDS drugEmpajenta Tab. 10/5mg2025-11-28
    Drug · Prescription · Approval202503120
  • MFDS drugSaccine Plaster2025-11-28
    Drug · OTC · Notification202503121
  • MFDS drugDaewoncol ibu nose Soft Cap.2025-11-28
    Drug · OTC · Notification202503123
  • MFDS drugEmpajenta Tab. 25/5mg2025-11-26
    Drug · Prescription · Approval202503083
  • MFDS drugDaewonco ibu cough Soft Cap.2025-11-19
    Drug · OTC · Notification202503021
  • MFDS drugDaewoncol ibu cold Soft Cap.2025-11-19
    Drug · OTC · Notification202503022
  • MFDS drugDaewoncol cough Soft cap.2025-10-17
    Drug · OTC · Notification202502688
  • MFDS drugDaewoncol cold Soft Cap.2025-10-17
    Drug · OTC · Notification202502690
  • MFDS drugDaewoncol nose Soft Cap.2025-10-02
    Drug · OTC · Notification202502618
  • MFDS drugCodaewon Plus Tab.2025-09-28
    Drug · Prescription · Approval202502560
  • MFDS drugmy toktok care eye drops2025-08-04
    Drug · OTC · Notification202502031
  • MFDS drugEmpasita M XR Tab. 5/50/750mg2025-07-30
    Drug · Prescription · Approval202501987
  • MFDS drugEmpasita M XR Tab.12.5/50/750mg2025-07-30
    Drug · Prescription · Approval202501988
  • MFDS drugEmpamet XR Tab. 5/1000mg2025-07-25
    Drug · Prescription · Approval202501911
  • MFDS drugEmpamet XR Tab. 12.5/750mg2025-07-25
    Drug · Prescription · Approval202501912
  • MFDS drugEmpamet XR Tab. 5/750mg2025-07-25
    Drug · Prescription · Approval202501913
  • MFDS drugEmpamet XR Tab. 12.5/1000mg2025-07-25
    Drug · Prescription · Approval202501914
  • MFDS drugColdaewon kids cold S Syrup2025-07-03
    Drug · OTC · Notification202501659
  • MFDS drugEmpasita M XR Tab. 10/100/1000mg2025-06-20
    Drug · Prescription · Approval202501536
  • MFDS drugEmpasita M XR Tab.25/100/1000mg2025-06-20
    Drug · Prescription · Approval202501537
  • MFDS drugEmpasita Tab.10/100mg(Empagliflozin, Sitagliptin)2025-06-12
    Drug · Prescription · Approval202501433
  • MFDS drugEmpasita Tab.25/100mg(Empagliflozin, Sitagliptin)2025-06-12
    Drug · Prescription · Approval202501434
  • MFDS drugEmpamet XR Tab. 25/1000mg2025-04-03
    Drug · Prescription · Approval202500781
  • MFDS drugEmpamet XR Tab. 10/1000mg2025-04-03
    Drug · Prescription · Approval202500782
  • MFDS drugDaewon Cucurbit Soft Capsule Cap.2025-03-24
    Drug · OTC · Notification202500661
  • MFDS drugV Cold Syrup2024-12-31
    Drug · OTC · Notification202403109
  • MFDS drugV Cold K Syrup2024-12-16
    Drug · OTC · Notification202402974
  • MFDS drugV Cough Syrup2024-12-13
    Drug · OTC · Notification202402956
  • MFDS drugSaccine Cool gel(Piroxicam)2024-08-13
    Drug · OTC · Notification202401954
  • MFDS drugCHAJALTHA Sol.2024-07-25
    Drug · OTC · Notification202401797
  • MFDS drugTerrosa prefilled pen2024-07-08
    Drug · Prescription · Approval202401682
  • MFDS drugNeuroginkgo Tab. 240mg2024-04-11
    Drug · OTC · Notification202400818
  • MFDS drugLitozet Tablet 10/5mg(Ezetimibe, Atorvastatin calcium trihydrate)2024-03-21
    Drug · Prescription · Approval202400588
  • MFDS drugTralitin combi XR Tab.2.5/750mg2024-03-12
    Drug · Prescription · Approval202400516
  • MFDS drugTralitin combi XR Tab.2.5/1000mg2024-03-12
    Drug · Prescription · Approval202400517
  • MFDS drugSPIRACTONE TAB. 25mg2023-10-16
    Drug · Prescription · Approval202302921
  • MFDS drugColdaewon Nose-QS Syrup2023-10-16
    Drug · OTC · Notification202302925
  • MFDS drugTralitin combi XR Tab.5/1000mg2023-10-13
    Drug · Prescription · Approval202302914
  • MFDS drugColdaewon Night Syrup2023-09-27
    Drug · OTC · Notification202302835
  • MFDS drugEmpamet tab. 12.5/1000mg2023-09-05
    Drug · Prescription · Approval202302639
  • MFDS drugEmpamet tab. 12.5/850mg2023-09-05
    Drug · Prescription · Approval202302640
  • MFDS drugEmpamet tab. 12.5/500mg2023-09-05
    Drug · Prescription · Approval202302641
  • MFDS drugMonteleple tab.2023-08-25
    Drug · Prescription · Approval202302521
  • MFDS drugJanupio Tab. 100/30mg(Sitagliptin/Pioglitazone)2023-07-31
    Drug · Prescription · Approval202302301
  • MFDS drugJanupio Tab. 100/15mg(Sitagliptin/Pioglitazone)2023-07-31
    Drug · Prescription · Approval202302302
  • MFDS drugDapasita-M SR tab.2023-06-30
    Drug · Prescription · Approval202302018
  • MFDS drugDapasita-M SR tab. 5/50/500mg2023-06-30
    Drug · Prescription · Approval202302019
  • MFDS drug5/50/1000mg2023-06-30
    Drug · Prescription · Approval202302020
  • MFDS drugDapasita Tab. 10/100mg2023-06-07
    Drug · Prescription · Approval202301759
  • MFDS drugTavalozet 4/10mg2023-05-25
    Drug · Prescription · Approval202301671
  • MFDS drugTavalozet 2/10mg2023-05-25
    Drug · Prescription · Approval202301672
  • MFDS drugDapasita-M SR tab. 10/100/1000mg2023-05-22
    Drug · Prescription · Approval202301622
  • MFDS drugDAEWON HEDERA Syrup(Ivy Leaf 30% Ethanol Dried Extract(5~7.5->1))2023-02-10
    Drug · OTC · Notification202300506
  • MFDS drugJanulitin Combi XR Tab. 50/750mg2023-01-02
    Drug · Prescription · Approval202300021
  • MFDS drugDapawon M XR Tab. 10/500mg2022-11-18
    Drug · Prescription · Approval202204139
  • MFDS drugDapawon M XR Tab. 5/1000mg2022-11-18
    Drug · Prescription · Approval202204140
  • MFDS drugDapawon M XR Tab. 5/500mg2022-11-18
    Drug · Prescription · Approval202204141
  • MFDS drugDapawon M XR Tab. 10/1000mg2022-11-16
    Drug · Prescription · Approval202204123
  • MFDS drugmy toktok pure eye drop(single use)2022-08-23
    Drug · OTC · Notification202203353
  • MFDS drugTolvis2022-07-28
    Drug · Prescription · Approval202203114
  • MFDS drugTolvis2022-07-28
    Drug · Prescription · Approval202203115
  • MFDS drugJanuritin Combi XR Tab. 50/500mg2022-05-11
    Drug · Prescription · Approval202201933
  • MFDS drugJanuritin Combi XR Tab. 50/1000mg2022-05-11
    Drug · Prescription · Approval202201934

Showing the 80 most recent of 389 records.

Clinical trials

data.go.kr

148 MFDS clinical trial authorisations · 2012–2026 (Phase 1 63 · Bioequivalence 54 · Phase 3 21 · Phase 2 5 · Phase 2a 2)

  • Phase 1DW44212026-06-12

    1 trial site

  • BioequivalenceDW6521-T12026-05-15

    1 trial site

  • Phase 1DW44212026-01-12

    1 trial site

  • Phase 1DW44212025-12-30

    1 trial site

  • Phase 1DW55242025-11-26

    1 trial site

  • Phase 1DW44212025-11-06

    1 trial site

  • Phase 3DW44212025-10-27

    20 trial sites

  • Phase 3DW44212025-10-15

    18 trial sites

  • Phase 1DW44212025-09-29

    1 trial site

  • BioequivalenceDW65212025-09-10

    1 trial site

  • Phase 1DW54212025-07-28

    2 trial sites

  • BioequivalenceDW65212025-03-27

    1 trial site

Show 68 more
  • Phase 1DW51242025-02-07

    1 trial site

  • BioequivalenceDW-22222024-12-13

    1 trial site

  • Phase 1DW44212024-10-09

    2 trial sites

  • Phase 3DW54212024-08-26

    18 trial sites

  • Phase 3DW18072024-05-14

    21 trial sites

  • Phase 1DW12222024-04-09

    1 trial site

  • Phase 1DW12222024-04-08

    1 trial site

  • Bioequivalence엠파젠타정 25/5밀리그램2024-03-11

    2 trial sites

  • Phase 1DW10222024-03-04

    3 trial sites

  • Phase 1DW12222024-02-08

    1 trial site

  • Phase 2DW44212024-02-08

    9 trial sites

  • Phase 1DW12222024-01-24

    1 trial site

  • Phase 1DW10262024-01-18

    2 trial sites

  • Phase 3DW51212023-11-30

    8 trial sites

  • Phase 1DW11222023-09-18

    2 trial sites

  • Phase 1DW11222023-09-07

    2 trial sites

  • BioequivalenceDW21222023-08-14

    1 trial site

  • Phase 1DW11222023-08-08

    2 trial sites

  • Phase 1DW11222023-08-02

    2 trial sites

  • Phase 1DW10212023-07-04

    1 trial site

  • BioequivalenceDW51252023-02-27

    2 trial sites

  • BioequivalenceDW51222022-12-29

    2 trial sites

  • Phase 1DW51212022-11-29

    1 trial site

  • Phase 1DW1125, DW1125A2022-08-16

    2 trial sites

  • Phase 1DW10262022-07-25

    2 trial sites

  • Bioequivalence에스원엠프정40mg2022-07-19

    2 trial sites

  • Phase 3DW10262022-06-27

    26 trial sites

  • BioequivalenceDWCLDS1252022-06-21

    2 trial sites

  • BioequivalenceDW51252022-05-30

    2 trial sites

  • BioequivalenceDW52212022-05-13

    2 trial sites

  • BioequivalenceDW51222022-05-13

    2 trial sites

  • BioequivalenceDWCLDS2502022-04-18

    2 trial sites

  • Phase 3DW1125, DW1125A2022-04-01

    25 trial sites

  • Bioequivalence엠파젠타정 25/5밀리그램2022-03-25

    2 trial sites

  • Phase 1DW43012022-03-10

    2 trial sites

  • Bioequivalence핀카정2022-01-17

    2 trial sites

  • Bioequivalence에스원엠프정40mg2022-01-14

    2 trial sites

  • Phase 1DW10252021-12-02

    2 trial sites

  • Phase 2DWTG51012021-11-02

    4 trial sites

  • Phase 1DW10292021-07-02

    1 trial site

  • Phase 2/3DW17042021-06-14

    9 trial sites

  • Phase 1DW18052021-05-18

    1 trial site

  • Phase 2DW43012021-04-20

    7 trial sites

  • Phase 1DW18052021-04-13

    1 trial site

  • Phase 3DWKH2021-01-29

    8 trial sites

  • Bioequivalence에스원엠프정40mg2021-01-04

    2 trial sites

  • Phase 2DW49022020-10-21

    12 trial sites

  • Phase 3DW19032020-10-13

    27 trial sites

  • Phase 1DW18062020-08-11

    2 trial sites

  • Phase 1DW1808-T1, DW1808-T22020-07-23

    2 trial sites

  • Phase 1DW1808-T1, DW1808-T22020-07-17

    2 trial sites

  • Phase 1DW19022020-07-10

    2 trial sites

  • Bioequivalence칸디나캡슐(플루코나졸)2020-07-02

    2 trial sites

  • Phase 1DW1809-T22020-07-02

    2 trial sites

  • Phase 1DW18092020-06-24

    2 trial sites

  • Phase 1DW18072020-05-14

    2 trial sites

  • Bioequivalence원살탄플러스에프정2020-05-12

    2 trial sites

  • BioequivalenceDW28012020-05-08

    2 trial sites

  • BioequivalenceDW2802-T2020-04-22

    2 trial sites

  • Phase 1DW19022020-03-30

    2 trial sites

  • Phase 1DW19032020-03-10

    1 trial site

  • Phase 3펠루비서방정(펠루비프로펜)2020-02-04

    12 trial sites

  • Phase 1DW18062020-01-03

    2 trial sites

  • Phase 1DW18092019-10-31

    2 trial sites

  • Phase 1DW18072019-10-11

    1 trial site

  • Phase 1DW15032019-10-08

    2 trial sites

  • Phase 1bDW43012019-10-04

    2 trial sites

  • Bioequivalence알포콜린연질캡슐(콜린알포세레이트)2019-09-30

    2 trial sites

Showing the 80 most recent of 148 records.

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 38 more trials

R&D and key agreements

Source: DART corporate disclosure

TU2670 · 자궁근종/자궁내막증 · 국내 2상(자궁근종) 종료, 유럽 2a상(자궁내막증) 종료 · Domestic exclusive license from Tium Bio's NCE403 program candidate

DW-4121 · 폐암 · 국내 1상 준비중, 유럽 1상 준비중 · CAGE inhibition mechanism; licensed from L base under a 2021 agreement (KRW 1bn upfront paid)

DW-4222 · 비만 · 국내 2a상 완료 · PON2-binding mechanism enhancing mitochondrial function; licensed from Glaceum (2022)

DW-4321 · 당뇨·비만 · 후보물질발굴단계 · Triple agonist (GLP-1/GIP/GCG); joint research and license agreement with Farmus Bioscience (2023)

DW-4421 · 위식도역류질환(미란성·비미란성) · 국내 2상 종료, 국내 3상 진행중 · P-CAB (potassium-competitive acid blocker); co-developed and licensed with Yunovia (2024)

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 92 more patents

AI reads

MAA server logs · IP-verified
257
Times AI engines pulled DAEWON PHARMACEUTICAL CO.,LTD's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

3
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

254
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

16
live 0
Last 7 days
191
live 1
Last 30 days
257
live 3
All time
  • OpenAIChatGPT-Userlive3
  • OpenAIOAI-SearchBot200
  • GoogleGoogleOther37
  • PerplexityPerplexityBot13
  • MicrosoftBingbot2
  • AnthropicClaudeBot2

Measured since Aug 25, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for DAEWON PHARMACEUTICAL CO.,LTD and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Celltrion Pharm Inc.1 shared

Celltrion Pharm holds exclusive domestic distribution rights for 12 Celltrion biologics and manufactures the liver drug Godex.

IL DONG PHARMACEUTICAL CO., LTD.1 shared

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

SHINHUNG CO.,LTD1 shared

Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

AHN-GOOK PHARMACEUTICAL Co., Ltd.85

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.85

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition